A genome-first approach to aggregating rare genetic variants in LMNA for association with electronic health record phenotypes

[1]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[2]  Francis S. Collins,et al.  Human laminopathies: nuclei gone genetically awry , 2006, Nature Reviews Genetics.

[3]  J. Genschel,et al.  Mutations in the LMNA gene encoding lamin A/C , 2000, Human mutation.

[4]  A. Marian,et al.  Causality in genetics: the gradient of genetic effects and back to Koch's postulates of causality. , 2014, Circulation research.

[5]  Shamil R Sunyaev,et al.  Pooled association tests for rare variants in exon-resequencing studies. , 2010, American journal of human genetics.

[6]  D. G. MacArthur,et al.  Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.

[7]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[8]  David L. Masica,et al.  Assessing the Pathogenicity of Insertion and Deletion Variants with the Variant Effect Scoring Tool (VEST‐Indel) , 2015, Human mutation.

[9]  Melissa A. Basford,et al.  Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data , 2013, Nature Biotechnology.

[10]  Karynne E. Patterson,et al.  The Genetic Basis of Mendelian Phenotypes: Discoveries, Challenges, and Opportunities. , 2015, American journal of human genetics.

[11]  A. Marian.  Erratum: Causality in genetics: the gradient of genetic effects and back to Koch postulates of causality (American Journal of Surgical Pathology (2014) 114 (e18-e21) DOI: 10.1161/ CIRCRESAHA.114.302904) , 2014 .

[12]  R. Hershberger,et al.  Clinical and genetic issues in familial dilated cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[13]  H. Carter,et al.  Identifying Mendelian disease genes with the Variant Effect Scoring Tool , 2013, BMC Genomics.

[14]  S. Young,et al.  Modulation of LMNA splicing as a strategy to treat prelamin A diseases. , 2016, The Journal of clinical investigation.

[15]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[16]  H. Worman,et al.  "Laminopathies": a wide spectrum of human diseases. , 2007, Experimental cell research.

[17]  Lee-Jen Wei,et al.  Pooled Association Tests for Rare Variants in Exon-Resequencing Studies , 2010 .

[18]  Marylyn D. Ritchie,et al.  Genetic identification of familial hypercholesterolemia within a single U.S. health care system , 2016, Science.

[19]  Joshua C. Denny,et al.  R PheWAS: data analysis and plotting tools for phenome-wide association studies in the R environment , 2014, Bioinform..

[20]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[21]  Evan E. Eichler,et al.  A Genotype-First Approach to Defining the Subtypes of a Complex Disease , 2014, Cell.

[22]  E. Bertini,et al.  Phenotypic clustering of lamin A/C mutations in neuromuscular patients , 2007, Neurology.

[23]  A. Ong,et al.  Cosegregation of Focal Segmental Glomerulosclerosis in a Family with Familial Partial Lipodystrophy due to a Mutation in LMNA , 2013, Nephron Clinical Practice.

[24]  Trevor Hastie,et al.  REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.

[25]  T. Edvardsen,et al.  Lamin A/C cardiomyopathy: young onset, high penetrance, and frequent need for heart transplantation , 2017, European heart journal.

[26]  C. Newton-Cheh.  Should Identifying a Titin Truncating Variant Change the Management of Patients With Dilated Cardiomyopathy? , 2017, Journal of the American College of Cardiology.

[27]  L. Mestroni,et al.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations. , 2003, Journal of the American College of Cardiology.

[28]  Magalie S Leduc,et al.  Molecular findings among patients referred for clinical whole-exome sequencing. , 2014, JAMA.

[29]  Gill Bejerano,et al.  M-CAP eliminates a majority of variants of uncertain significance in clinical exomes at high sensitivity , 2016, Nature Genetics.

[30]  Justin C. Fay,et al.  Identification of deleterious mutations within three human genomes. , 2009, Genome research.

[31]  H. Mefford.  Genotype to phenotype—discovery and characterization of novel genomic disorders in a “genotype-first” era , 2009, Genetics in Medicine.

[32]  Alexander E. Lopez,et al.  Profiling and leveraging relatedness in a precision medicine cohort of 92,455 exomes , 2017, bioRxiv.

[33]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[34]  D. Ledbetter,et al.  The Geisinger MyCode Community Health Initiative: an electronic health record-linked biobank for Precision Medicine research , 2015, Genetics in Medicine.

[35]  T. Ishida,et al.  A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease , 2009, Endocrine.

[36]  S. Deshpande,et al.  Genetic Testing in Pediatric Cardiomyopathy , 2018, Pediatric Cardiology.

[37]  Marylyn D. Ritchie,et al.  A simulation study investigating power estimates in phenome-wide association studies , 2017, BMC Bioinformatics.

[38]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.

[39]  Andres Metspalu,et al.  Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population , 2014, PLoS genetics.

[40]  Jana Marie Schwarz,et al.  MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.

[41]  F. Anselme,et al.  Implantable cardioverter-defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. , 2013, Heart rhythm.